Status:
NOT_YET_RECRUITING
Efficacy of Non-invasive Neuromodulation Treatments for COVID-19 Sequelae
Lead Sponsor:
Clinica Gema Leon
Conditions:
Covid-19 Recurrent
Eligibility:
All Genders
18-60 years
Phase:
NA
Brief Summary
The goal of this clinical trial is to demonstrate the effectiveness of non-invasive Neuromodulation as a therapy in neurological, respiratory and musculoskeletal pathologies derived from the consequen...
Detailed Description
The waves of Sars-Cov-2 disease continue to be continuous and we are increasingly aware of the consequences it causes both in the respiratory system, musculoskeletal system and in the central and peri...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Patients between the ages of 18 and 60.
- Patients with a positive diagnosis of COVID-19.
- Patients with post-COVID-19 sequelae with musculoskeletal, respiratory or neurological symptoms due to taste or smell lasting at least 30 days, with no history of respiratory and/or neurological and/or musculoskeletal diseases.
- Patients who signed the informed consent.
- Exclusion criteria:
- Patients aged before 18 years and after 60 years.
- Healthy people with no history of neurological, neurological and/or respiratory and/or musculoskeletal diseases
- Patients with secondary diseases that could directly affect the systems to be evaluated who were not diagnosed positive for COVID-19.
Exclusion
Key Trial Info
Start Date :
January 1 2026
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 30 2026
Estimated Enrollment :
104 Patients enrolled
Trial Details
Trial ID
NCT06544395
Start Date
January 1 2026
End Date
December 30 2026
Last Update
September 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Gema León Physiotherapy and Rehabilitation Clinic
Córdoba, Andalusia, Spain, 14011